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Introduction
Cystic Fibrosis (CF) is the most prevalent autosomal-re-
cessive hereditary disease in the Caucasian population. 
The disease is due to mutations in the gene encoding 
the Cystic Fibrosis Transmembrane Conductance Regu-
lator (CFTR) protein. There are about 1800 CFTR mu-
tations. Most of them are worldwide distributed, while 
some are purely regional or “familial” and some others 
are unique to certain ethnic groups. The CF median birth 
incidence is 1:3500 in Europe, whereas the overall birth 
prevalence in the United States is about 1 in 3,700. It 
is estimated that 1 in 2,500 White births are affected in 
comparison to 1 in 13,500 Hispanics, 1 in 15,100 Afri-
can Americans, and 1 in 31,000 to more than 100,000 
Asians [1-3]. In the past, CF used to be a predominantly 
paediatric disease with the onset of symptoms in child-
hood and a typically unfavourable prognosis within the 
first decade of life. Recently, the epidemiological pro-
file has changed with almost half of these patients be-
ing now adults, reflecting a clear improvement in patient 
management [4]. Moreover, genetic testing methods are 
able to detect couples at risk, and many families with a 
CF child use prenatal diagnosis to prevent the birth of 
other affected children.
CF disease is characterized by chronic endobronchial 
infections and a progressive obstructive lung disease. 
As a consequence of CFTR mutations, the production of 
dehydrated bronchial mucus promotes the colonization 
of the airways by microorganisms and makes them less 
sensitive to defence mechanisms, as well as to antibiotic 
therapy. Staphylococcus aureus and Pseudomonas aeru-
ginosa are still the most frequently detected bacteria in 
CF patients, but the prevalence of Burkholderia cepacia 
has risen in recent years, resulting in increasing rates of 
morbidity and mortality [5]. Less frequently, moulds 
have been also reported to colonize the respiratory tract, 
sometimes leading to various respiratory infections [6, 
7]. The most common is the allergic bronchopulmonary 
aspergillosis (ABPA). Aspergillus fumigatus has also 
been described as a possible cause of lung deterioration 
in the absence of ABPA [8], while Scedosporium ap-
iospermum has been described as a cause of a pulmonary 
or a disseminated disease [9, 10].
The Italian Registry of Cystic Fibrosis (IRCF) has been 
active in Rome since January 1, 1988. Its aims are to col-
lect patient demographic data, to increase knowledge of 
the disease, and to monitor epidemiological trends. This 
registry indicates that the CF incidence in Italy is 1:4238 
live births, with wide variations among regions. 43% of 
patients are older than 18 years, 23.5% were diagnosed 
within the first year of life, and 16.7% after the age of 18 
years. The CF incidence in the Southern Italy is not re-
ported [11]. On January 1, 1994 a new Italian Law (Law 
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Objective. This study aim was to determine the prevalence of 
microorganisms in the respiratory tract of patients with cystic 
fibrosis (CF) admitted to the CF Reference Centre in Southern 
Italy between 2002-2010.
Methods. Microbiology assessment of samples (sputum and tra-
cheal aspirates) collected from patients with pulmonary exacer-
bation admitted to hospital was carried out. All patients were reg-
istered in a database and clinical and microbiological data were 
retrospectively analysed.
Results. Overall, 188 patients were included and a total of 1217 
samples were analysed. The most common microorganisms were 
Staphylococcus aureus (78.7% of the patients) and Pseudomonas 
aeruginosa (58%), followed by Candida albicans (19.1%), Hae-
mophilus influenzae (13.3%) and Aspergillus fumigatus (9.6%).
Conclusion. Compared to similar studies performed in other 
European countries, our microbiological data, especially the low 
occurrence of filamentous fungi, suggest a specific local epide-
miology, probably related to some uncommon CFTR mutations, 
which are specific to Southern Italy. 
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No.548) established a network of specialized Reference 
Centres across regions aiming at preventing, diagnos-
ing and treating complications, as well as coordinating 
medical, social and research aspects.
The aim of the present study was to determine the preva-
lence of microorganisms (bacteria and fungi) in the res-
piratory tract of the patients admitted to the CF Refer-
ence Centre of South Italy between 2002 and 2010.
Materials and methods
The CF Reference Centre of Southern Italy is located 
in a large University Hospital in Apulia. It admits 260 
patients per year in follow up (with about 12 new diag-
nosis per year) and hosts clinics, laboratories, facilities 
and services, all meeting the standards of care for CF 
patients.
The follow-up of CF patients at this Centre requires peri-
odic medical check-ups with a frequency appropriate for 
the severity of the disease (at least every 4 months) and 
admission programs aimed at early detection of com-
plications of this disease (i.e. diabetes mellitus, chronic 
liver disease). A microbiological analysis of respiratory 
secretions is carried out only during the pulmonary ex-
acerbation.
Study design
The clinical diagnosis was established on the basis of the 
results of 2 positive sweat chloride tests (> 60mEq/L) by 
Gibson and Cooke [12] procedure, and the identification 
of two CF-disease causing mutations in trans [13, 14].
Since 2002, all CF patients with a microbiological anal-
ysis of sputum or tracheal aspiration positive for bacteria 
and/or fungi were included in our study and entered in 
a database (Microsoft Access 2003). Categorical vari-
ables were expressed as proportions or percentages, and 
numerical data as the mean + SD and range. Bivariate 
analyses were performed using Student’s t-test, with P-
value < 0.05 considered significant. Statistical analysis 
was performed using the software SAS system version 
9.2. 
Laboratory procedures
For bacteriological cultures, sputum samples and trache-
al aspirations were homogenized with N-acetyl-cysteine 
(Carlo Erba reagent SpA, Milano, Italy) and inoculated 
in parallel on the following media: Columbia with 5% 
sheep blood agar (CNA, bioMérieux, Marcy l’Etoile, 
France), Haemophilus Chocolate agar 2 with Bacitracin 
(HAE2, bioMérieux), MacConkey agar (Becton-Dick-
inson, Heidelberg, Germany), Oxidation/Fermentation-
Polymyxin-Bacitracin-Lactose agar (OFPBL, Becton-
Dickinson) and Mannitol Salt Agar (Becton-Dickinson). 
All plates were incubated for 24-72 hours at 37°C.
For mycological cultures, samples were inoculated on 
two Sabouraud-chloramphenicol-dextrose agar plates 
(SC2, bioMérieux) which were incubated at 30°C and 
37°C, respectively and examined daily up to 10 days.
The bacteria and yeasts identifications were performed 
using VITEK-2 System (bioMérieux). Filamentous fun-
gi were identified on the basis of their macroscopic and 
microscopic morphological features, according to stand-
ard descriptions.
Results
From 2002-2010, a total of 1,217 samples from 188 CF 
patients admitted to CF Reference Centre were ana-
lysed. 
Table I summarizes the demographic, clinical and ge-
netic data of these patients. The male:female ratio was 
86:102 (45.7% vs 54.3%), ages ranged from 1 month to 
68 years old, and a mean age at date of CF diagnosis of 
17.9 ± 12.8 years. In particular 70 out of 188 patients 
(37.2%) were less than 10 years old; in addition, females 
resulted more frequently affected than males in the first 
(62.9% vs 37.1%) and in the fourth (68% vs 32%) dec-
ade of life. 
Tab. I. demographic, clinical and genetic data from 188 enrolled CF 




males/Females                                                                           86/102
(45.7% vs 54.3%)
Age range (years) 0-68
mean age at date of CF diagnosis (years) 17.9 ± 12.8
pancreatic insufficiency 114 (60.6%)
diabetes mellitus  12  (6.4%)
Fev1 (% predicted)  63.68 ± 28.22
Bmi (Z score) 19.51 ±  4.06
F508del / F508 del  38  (20.2%)
F508del / Other mutation 83 (44.1%)
Other / Other mutation                                                                         63 (33.5%)
genotype incomplete or unknown 4 (2.1%)
Unless otherwise stated, data are presented as mean ± Sd. Fev1: forced 
expiratory volume in 1 s; Bmi: body mass index.
Thirty-eight out of 188 patients (20.2%) were found ho-
mozygous for the F508del mutation. Among other pa-
tients, 83 (44.1%) were found heterozygous for F508del 
mutation, 63 (33.5%) both homozygous and compound 
heterozygous for other mutations, 4 (2.1%) had CF chro-
mosomes not yet genetically identified. 
Other found mutations were N1303K (12.8%) and G542X 
(7.4%). Uncommon mutations, specific to CF chromo-
somes from Southern Italy [15], were 4382delA (9.6%), 
1259insA (5.3%), 852del22 (5.3%), G1349D (4.8%), 
D579G and R1158X (3.2%), I502T (2.7%) and L1077P 
(2.1%). Overall, 52 different mutations in various fre-
quency and genetic combination, were found in our study. 
Interestingly, 127 (67.5%) and 57 (30.3%) patients had 
severe and mild CFTR mutations, respectively. 
Table II shows the bacteria isolated from clinical sam-
ples collected from 188 patients. Staphylococcus aureus 
and Pseudomonas aeruginosa were the most frequent 
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(78.7% and 58%, respectively), followed by Haemo-
philus influenzae (13.3%), Haemophilus parainfluen-
zae (8%), Burkholderia cepacia complex (6.9%), and 
Stenotrophomonas maltophilia (6.4%). Other bacterial 
species, such as Achromobacter xylosoxidans, Proteus 
mirabilis, Serratia marcescens, Enterobacter cloacae, 
Escherichia coli, Streptococcus pneumoniae, Acineto-
bacter baumannii and Klebsiella pneumoniae were oc-
casionally isolated, often occurring in mixed cultures. 
Overall, the mucoid phenotype of P. aeruginosa was 
identified in 81% of cases.
Regarding bacteria known as the most relevant in the 
respiratory tract of CF patients, S. aureus and P. aeru-
ginosa were isolated mostly in combination with other 
bacteria and/or fungi, while B. cepacia complex was de-
tected in combination only with other bacteria or in a 
pure culture (Tab. III).
CF patients positive for S. aureus and P. aeruginosa at 
their first microbiological control were grouped by age. 
Figure 1 shows that S. aureus was the most common 
species isolated during the first decade of life. Its fre-
quency progressively decreased until the fourth decade, 
together with a concomitant increase in the prevalence 
of P. aeruginosa. Very close isolation percentage were 
seen for these two species during the third decade of 
life; whereas the latter became the predominant species 
in older patients (31% vs 79.3% for patients aged 31-
40). Among the enrolled patients, 15 (11 females and 4 
males, aged between 7 and 42 years) were continuously 
positive for S. aureus and/or P. aeruginosa in all exam-
ined clinical samples. The remaining patients resulted 
positive for other species.
Mycological investigations were positive in 52 out of 
188 patients (27.6%) (Tab. IV). 
Candida albicans was the most frequent fungus (19.1%), 
followed by Aspergillus fumigatus (9.6%), Aspergillus 
flavus (2.1%), Candida glabrata and Scedosporium ap-
iospermum (0.5%), mainly in combination with bacteria 
(usually S. aureus and P. aeruginosa, and to a lesser ex-
tent S. maltophilia). 
Sequential clinical samples were obtained from 129 
patients during a period longer than 3 years. From the 
analysis of these samples, a high persistence (81.3%) 
was observed for B. cepacia, lower for P. aeruginosa 
(50.9%) and S. aureus (38.6%). Regarding to myco-
logical investigations, a high persistence was observed 
for A. fumigatus and A. flavus (54.1% and 50%, respec-
tively).
Tab. II. Overall bacterial species isolated from CF patients admitted to CF reference Centre during the study period (2002-2010).
Isolates Positive patients (n = 188) Patients positive in:
pure cultures mixed cultures
N % N % N %
S. aureus 148 78.7 37 25 111 75.0
p. aeruginosa 109 58.0 16 14.7 93 85.3
h. influenzae 25 13.3 2 8.7 23 90.3
h. parainfluenzae 15 8.0 - - 15 100
B. cepacia 13 6.9 1 7.7 12 92.3
S. maltophilia 12 6.4 1 8.3 11 91.6
A. xylosoxidans 5 2.7 - - 5 100
p. mirabilis 4 2.1 - - 4 100
S. marcescens 4 2.1 - - 4 100
e. cloacae 3 1.6 1 33.3 2 66.7
e. coli 3 1.6 - - 3 100
S. pneumoniae 2 1.0 - - 2 100
A. baumannii 1 0.5 - - 1 100
K. pneumoniae 1 0.5 - - 1 100
Frequencies are calculated according to the number of CF patients (n = 188) who had at least one sputum sample or tracheal aspiration microbiologically 
positive during the study period.
Tab. III. distribution of the most relevant bacterial pathogens ob-
served in respiratory secretions from 188 CF patients admitted to CF 
reference Centre (2002-2010).




S. aureus 719 (59.1) 148 (78.7)
Alone 221 (30.7) 37 (25.0)
With other bacteria 332 (46.2) 68 (45.9)
With fungi 55   (7.6) 6   (4.1)
With fungi 
and bacteria 111 (15.4) 37 (25.0)
P. aeruginosa 725 (59.6) 109 (58.0)
Alone 250 (34.5) 16 (14.7)
With other bacteria 312 (43.0) 58 (53.2)
With fungi 72 (10.0) 3   (2.7)
With fungi 
and bacteria 91 (12.5) 32 (29.4)
B. cepacia 107   (8.8) 13   (6.9)
Alone 44 (41.1) 1   (7.7)
With other bacteria 63 (58.9) 12 (92.3)
With fungi 0 0
With fungi 
and bacteria 0 0
data correspond to the number of positive samples and of positive pa-
tients among the 1217 clinical samples and the 188 CF patients examined. 
in parentheses are indicated frequency percentages.
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Clinical outcomes were unfa-
vourable for 16/188 examined 
patients (8.5%). Of the remain-
ing patients, 12 underwent 
transplantation (lung, liver or 
renal transplantation in 6, 4 and 
2 patients, respectively). Three 
women completed a pregnancy, 
one with twins.
Discussion
It is widely known that a lung 
disease and recurrent lung in-
fections are the major cause of 
morbidity and mortality in CF 
patients [16]. Many patients 
follow a characteristic pattern 
of infection that begins in the early stages, usually in 
childhood, with S. aureus and H. influenzae infection. 
These microorganisms seem to prepare the bronchial tree 
for more aggressive microorganisms, such as P. aerugi-
nosa, typical in adolescent patients, often associated or 
replaced by B. cepacia complex in young adults [17]. 
Fortunately, today the ability of these bacteria to invade 
the respiratory tract is countered by new therapeutic pro-
tocols aiming at the eradication of the infection, which 
has significantly changed the prognosis in these patients 
[18].
In Apulia, a neonatal screening program is not yet op-
erational. In addition, the presence of many mild muta-
tions determines blurred clinical signs and infections 
caused by different etiological agents. Infact in our 
study, a wide variety of microorganisms was frequently 
recovered such as S. aureus, P. aeruginosa, A. fumiga-
tus, B. cepacia, etc, while others were seldom isolated 
(i.e. E. coli, C. glabrata, A. baumannii, S. apiosper-
mum). Staphylococcus aureus was the main detected 
bacterial species, particularly in the first decade of life 
and among the younger patients, than to P. aeruginosa 
(mean age 15.7 ± 11.1 and 22.3 ± 13.3, respectively; 
p < 0.001). Furthermore, S. aureus infection tended 
to become chronic in some patients, as demonstrated 
by repeated isolations in the years, in pure cultures for 
some patients or in combination with P. aeruginosa for 
others.
Pseudomonas aeruginosa was recovered from 58% of 
examined patients. According to other authors [19], it 
appeared in the first two decades of life with low fre-
quency, and increased up to 79% in adulthood. In these 
patients, chronic colonization of the respiratory tract 
was noted, especially by the mucoid phenotype and 
drug-resistant strains of P. aeruginosa, often related to 
a decline in lung function and a poor prognosis (unpub-
lished data).
Burkholderia cepacia complex is responsible for unfa-
vorable prognosis [20]. Although it was isolated with 
low frequency (6.9%), it showed a high persistence rate 
(> 80%) in our patients. 
In a retrospective study, Millar et al. [21] observed an 
important emergency of Stenotrophomonas maltophilia 
in CF patients, largely favouring the progression of lung 
disease. Valdezate et al. [22] reported that the same strain 
Tab. IV. Fungal communities in respiratory secretions from CF pa-





C. albicans 129 (10.6) 36 (19.1)
Alone 8   (6.2) 4 (11.1)
With bacteria 120 (93.0) 31 (86.1)
With other fungi 1   (0.8) 1   (2.8)
With other fungi 
and bacteria - - 
C. glabrata 1   (0.08) 1   (0.5)
Alone - -
With bacteria - -
With other fungi 1   (100) 1   (100)
With other fungi 
and bacteria - - 
A. fumigatus 100   (8.2) 18   (9.6)
Alone - -
With bacteria 81 (81.0) 10 (55.5)
With other fungi 8   (8.0) 2 (11.1)
With other fungi 
and bacteria 11 (11.0) 6 (33.3)
A. flavus 24   (2.0) 4   (2.1)
Alone - -
With bacteria 14 (58.3) 3 (75.0)
With other fungi - -
With other fungi 
and bacteria 10 (41.7) 1 (25.0)
S. apiospermum 20   (1.6) 1   (0.5)
Alone - -
With bacteria 20  (100) 1 (100)
With other fungi - -
With other fungi 
and bacteria - -
data correspond to the number of positive samples and of positive pa-
tients among the 1217 clinical samples and the 188 CF patients examined.
Fig. 1. isolation percentage of S. aureus and p. aeruginosa according to the age of the patients 
at first microbiological control.
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of S. maltophilia was isolated 11 times in seven years 
from one patient, and other subjects showed chronic 
S. maltophilia infection especially in addition with P. 
aeruginosa. Also in our study S. maltophilia was fre-
quently isolated, representing the sixth bacterial species 
from polymicrobial cultures and the eighth species when 
fungi were included. It appeared in association with S. 
aureus in 91.2% of cases, and to a lesser extent with P. 
aeruginosa and A. fumigatus. 
Regarding to results of mycological surveillance, the 
overall frequency of fungal isolation did not appear high 
in our patients (27.6%), although there was no prophy-
lactic antifungal treatment, in line with the protocols 
of our CF Reference Centre. Our data, especially the 
low occurrence of filamentous fungi (i.e. A. fumigatus 
9.6%), are conflicting with those obtained in similar 
studies performed in other European countries [23, 24], 
suggesting a particular local epidemiology. 
In Apulia, there are many mutations (about 60) from dif-
ferent classes and with different phenotypic outcomes; 
some of these are specific to Southern Italy and others 
are private mutations [15, 25]. Recently, Green et al. 
[26] asserted that the mutations, which determine a mild 
genotype by retaining some residual CFTR function, 
may result in a delay in the colonization of the respira-
tory tract by some microorganisms. In our study, 30.3% 
of patients had mild genotype, and only 21% of them 
had mycological cultures positive. Recently, some au-
thors emphasized that the transition from colonization 
to fungal infection, as well as the course of CF disease, 
are not only based on the genetic structure but are also 
determined by other genetic factors, so-called “modu-
lator genes” and by environmental factors [15, 27, 28]. 
The modulator genes produce proteins that can affect 
the clinical manifestations of CF disease. The interac-
tions between CFTR mutations and allelic modulators 
genes result in different phenotypic expressions and in 
part explain why individuals with the same genotype can 
have different level in severity of the disease. Moreover, 
the fungal genotype analyses conducted in recent years 
demonstrated that a dominant genotype tended to set-
tle with the ageing colonization [29, 30]. In our study, a 
persistent colonization with Aspergillus species was ob-
served for some patients. Besides, a patient, after coloni-
zation by A. fumigatus, was infected by S. apiospermum 
of which an unique genotype was identified. Twelve 
months later, the patient died after a cerebral involve-
ment, despite antifungal treatment [31].
This study suggests the need for an increased microbio-
logical monitoring in CF patients in order to determine 
whether the microbial flora is the same in a clinically 
stable phase and during an exacerbation, aiming at cor-
relating microbiological data to mutations and/or to 
clinical outcomes of these patients, defining possible 
therapeutic strategies that can prevent, or at least delay, 
new infections. Additionally, a better knowledge of local 
fungal epidemiology may be helpful, particularly when 
a decision regarding transplantation is made, which con-
sequently may contribute to improving life expectancy 
in CF patient population.
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